Ocumetics Technology Corp. Completes First Tranche of Private Placement

Calgary, Alberta — July 17, 2025 — NewsWall — Ocumetics Technology Corp. has completed the first tranche of its previously announced private placement, issuing 3,212,462 units at $0.35 per unit, raising gross proceeds of $1,124,362.

Each unit includes one common share and one-half of a common share purchase warrant. Whole warrants allow holders to buy an additional common share at $0.50 for 24 months from the warrant's issuance.

Numus Capital Corp. received $68,610 and warrants to purchase up to 196,029 common shares at $0.50 each for 24 months for their services as an agent in the first tranche.

The warrants and agent's warrants have an acceleration clause: if the common shares' volume-weighted average trading price on the TSX Venture Exchange is at least $0.60 for 30 consecutive trading days, Ocumetics can accelerate the expiry date to at least 30 days after notifying warrant holders via press release.

The total offering aims to raise up to $2,100,000 through the sale of up to 6,000,000 units at $0.35 each, with subsequent tranches planned. Net proceeds will fund ongoing research and development.

All securities issued under the private placement are subject to a four-month hold period. The TSX Venture Exchange has conditionally approved the closing of the private placement.

Michael Edwards, a director, participated in the private placement, making it a “Related Party Transaction” under Multilateral Instrument 61-101. The Corporation relied upon exemptions from minority shareholder approval and valuation requirements.

The directors of the Corporation unanimously approved the Private Placement. Because completion of the Private Placement was uncertain, a material change report was not filed 21 days before its completion.

Ocumetics Technology Corp. is dedicated to developing advanced vision correction solutions. They have developed an intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses.

Dean Burns, President and CEO, (817) 874-7564

Roger Jewett, Chief Financial Officer, roger.jewett@ocumetics.com

Source: Ocumetics Technology Corp.